Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06906874
PHASE2

Activated Charcoal Use in Chronic Kidney Disease Patients

Sponsor: Mansoura University

View on ClinicalTrials.gov

Summary

Hyperphosphatemia management is initially based on restricting dietary phosphorus intake. Hyperphosphatemia is almost always seen in patients on dialysis and may contribute to progressive vascular calcification. Considering that activated charcoal is generally well-tolerated and may have a favorable side effect profile compared to conventional phosphate binders, it presents a promising alternative. Until now, no clinical trial has primarily investigated the effect of activated charcoal on hyperphosphatemia in dialysis patients.

Official title: Efficacy and Safety of Activated Charcoal on Mineral Bone Disorder in Chronic Kidney Disease Patients

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2025-08

Completion Date

2025-11

Last Updated

2025-08-08

Healthy Volunteers

No

Interventions

DRUG

Activated Charcoal

oral activated charcoal capsules

DRUG

Phosphate Binders

calcium-based or non-calcium based (sevelamer) binders

Locations (1)

Urology and Nephrology Center

Al Mansurah, Please Select, Egypt